SCHEMBL5262276

SCHEMBL5262276

CCCCOC(=O)C(N)(CC(=O)O)c1cc(F)cc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.37
S1PR4 O95977 1/20 0.37
S1PR3 Q99500 1/20 0.37
S1PR5 Q9H228 1/20 0.37
ESR1 P03372 7/20 0.35
TSHR P16473 4/20 0.35
CYP3A4 P08684 2/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7445138 0.80 TSHR (0.49) S1PR1S1PR4S1PR3S1PR5ESR1
SCHEMBL5262277 0.75 TSHR (0.38) ESR1TSHRCYP3A4LMNACYP1A2
SCHEMBL7356658 0.69 CES2 (0.36) CYP1A2CYP2C19ALDH1A1THRB
SCHEMBL27596964 0.69 ALDH1A1 (0.42) S1PR1S1PR4S1PR3S1PR5TSHR
SCHEMBL3412121 0.68 ALDH1A1 (0.52) ESR1TSHRCYP3A4LMNACYP1A2
SCHEMBL30309035 0.67 ALDH1A1 (0.44) ESR1TSHRCYP3A4LMNACYP1A2
SCHEMBL18464342 0.67 ESR1 (0.65) ESR1TSHRCYP3A4LMNACYP1A2
SCHEMBL27315973 0.67 PIN1 (0.47) TSHRCYP2C19ALDH1A1HSD17B10THRB
SCHEMBL28137293 0.67 TSHR (0.51) TSHRCYP3A4LMNACYP1A2CYP2C19
SCHEMBL17848879 0.67 ALDH1A1 (0.47) TSHRCYP3A4ALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1789388-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS Elan Pharmaceuticals, Inc. (US) 2007-05-30 EP disclosed
WO-2006026532-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-03-09 WO disclosed